Article
Cardiac & Cardiovascular Systems
Moira Rushton, Coralea Kappel, Isac Lima, Meltem Tuna, Kathleen Pritchard, Steven Hawken, Susan Dent
Summary: This study investigated predictive factors for cardiac events in HER2+ breast cancer patients treated with trastuzumab and found that older age and longer treatment duration were associated with an increased risk of cardiac events.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Husam Abdel-Qadir, Felicia Tai, Ruth Croxford, Peter C. Austin, Eitan Amir, Oscar Calvillo-Arguelles, Heather Ross, Douglas S. Lee, Paaladinesh Thavendiranathan
Summary: This study focused on the prognosis of heart failure (HF) in women who developed HF after receiving anthracyclines or trastuzumab for early stage breast cancer. The results showed that patients with cardiotoxic exposure had fewer comorbidities compared to age-matched controls, and those who developed HF after trastuzumab treatment had a better prognosis than HF controls.
CIRCULATION-HEART FAILURE
(2021)
Review
Cardiac & Cardiovascular Systems
Agata Bikiewicz, Maciej Banach, Stephan von Haehling, Marek Maciejewski, Agata Bielecka-Dabrowa
Summary: Breast cancer is the most common cancer diagnosis in women, with significant progress in treatment but an increased risk of cardiovascular complications. Current recommendations suggest periodic monitoring of the cardiovascular system during treatment.
Article
Cardiac & Cardiovascular Systems
Husam Abdel-Qadir, David Bobrowski, Limei Zhou, Peter C. Austin, Oscar Calvillo-Arguelles, Eitan Amir, Douglas S. Lee, Paaladinesh Thavendiranathan
Summary: The study found that women exposed to statins had a lower risk of heart failure hospital presentations after chemotherapy for early breast cancer involving anthracyclines, with non-significant trends towards lower risk following trastuzumab. These findings support the development of randomized controlled trials of statins for prevention of cardiotoxicity.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2021)
Article
Multidisciplinary Sciences
Li Zhang, Yan Wang, Wenjing Meng, Weipeng Zhao, Zhongsheng Tong
Summary: This study evaluated the cardiac safety of anti-HER2-targeted therapy for early breast cancer and found that the combination of trastuzumab and pertuzumab did not significantly increase cardiac toxicity. High-sensitivity Troponin (hs-TnI) and QTc may be useful in monitoring and predicting cardiotoxicity associated with this therapy.
SCIENTIFIC REPORTS
(2022)
Article
Medicine, General & Internal
Sivisan Suntheralingam, Chun-Po Steve Fan, Oscar Calvillo-Arguelles, Husam Abdel-Qadir, Eitan Amir, Paaladinesh Thavendiranathan
Summary: This retrospective cohort study assessed the performance of three published risk prediction models in identifying the risk of Cancer-therapeutics-related cardiac dysfunction (CTRCD) during or immediately post treatment with trastuzumab therapy for HER2+ breast cancer. The results showed that these models can identify relative differences in CTRCD risk, but their ability to predict absolute risk is limited.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Anthony F. Yu, Zachary R. Moore, Chaya S. Moskowitz, Jennifer E. Liu, Chau T. Dang, Lakshmi Ramanathan, Kevin C. Oeffinger, Richard M. Steingart, Adam M. Schmitt
Summary: This study found that higher cardiomyocyte cfDNA level after completion of anthracycline chemotherapy was associated with risk of CTRCD. Quantification of cardiomyocyte cfDNA holds promise as a predictive biomarker for risk stratification of CTRCD among patients with breast cancer receiving cardiotoxic cancer therapy and requires further validation.
Article
Oncology
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger, N. Ponde, S. Guillaume, D. Parlier, M. Lambertini, A. Desmet, C. Caballero, C. Aguila, G. Jerusalem, J. M. Walshe, E. Frank, J. Bines, S. Loibl, M. Piccart-Gebhart, M. S. Ewer, S. Dent, C. Plummer, T. Suter
Summary: This study analyzed the cardiac safety of dual blockade with Pertuzumab and Trastuzumab in HER2-positive early breast cancer patients. The results showed that the use of Pertuzumab and Trastuzumab together did not increase the risk of cardiac events compared to Trastuzumab alone. Therefore, non-anthracycline chemotherapy may be considered in patients with cardiovascular risk factors.
Article
Oncology
Xuexin He, Jiali Ji, Xiaolan Dai, Aiham Z. Qdaisat, Francisco J. Esteva, Gabriel N. Hortobagyi, Sai-Ching J. Yeung
Summary: This study reviewed early HER2-positive breast cancer patients at the institution from 1998 to 2009 and found that hypertension and history of coronary artery disease were independent prognostic factors for late severe CV events. Combining anthracycline and anti-HER2 therapy regimens was beneficial for improving overall survival.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Lorenzo Livi, Giuseppe Barletta, Francesca Martella, Calogero Saieva, Isacco Desideri, Carlotta Bacci, Maria Riccarda Del Bene, Mario Airoldi, Domenico Amoroso, Luigi Coltelli, Vieri Scotti, Carlotta Becherini, Luca Visani, Viola Salvestrini, Matteo Mariotti, Fulvia Pedani, Marco Bernini, Luis Sanchez, Lorenzo Orzalesi, Jacopo Nori, Simonetta Bianchi, Iacopo Olivotto, Icro Meattini
Summary: The study aimed to evaluate whether pharmacological cardioprevention could reduce subclinical heart damage in breast cancer patients undergoing anthracycline-based chemotherapy. The results of the interim analysis suggested that cardioprotective pharmacological strategies were well tolerated and appeared to protect against cancer therapy-related left ventricular ejection fraction decline and heart remodeling.
Review
Oncology
Zhenkun Fu, Zhoujun Lin, Mao Yang, Chenggang Li
Summary: Breast cancer is a common type of cancer, with surgery being the preferred treatment method. Various adjuvant therapies such as radiotherapy, chemotherapy, endocrine therapy, and targeted drug therapy can also be used.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
George Koulaouzidis, Amanda E. Yung, Diana E. Yung, Karolina Skonieczna-Zydecka, Wojciech Marlicz, Anastasios Koulaouzidis, Dafni Charisopoulou
Summary: This meta-analysis identified a significant association between conventional cardiovascular risk factors such as age, hypertension, smoking, diabetes, family history of coronary artery disease, and known history of CAD with the development of trastuzumab-induced cardiotoxicity. Identifying these risk factors can help clinicians monitor and manage patients more effectively to prevent and manage cardiotoxicity.
CURRENT PROBLEMS IN CANCER
(2021)
Review
Biochemistry & Molecular Biology
Gabriel Mendez-Valdes, Francisca Gomez-Hevia, Maria Chiara Bragato, Jose Lillo-Moya, Catalina Rojas-Sole, Luciano Saso, Ramon Rodrigo
Summary: Breast cancer is the most common malignant neoplastic disease in women, and its treatment depends on patient and tumor characteristics. The overexpression of the HER2 receptor, found in 15-25% of tumors, is associated with aggressive behavior and poor prognosis. Trastuzumab, a monoclonal antibody used as targeted therapy against HER2 receptor overexpression, has a major concern of cardiotoxicity. This review aims to explore the use of antioxidants as adjuvant therapy to prevent trastuzumab-induced cardiac toxicity and improve its safety profile.
Article
Pharmacology & Pharmacy
Ping Huang, Jia-huan Huang, Ya-bing Zheng, Wen-ming Cao, Xi-ying Shao, Jun-qing Chen, Yuan Huang, Guang-liang Li, K. Sharma, Huan-huan Zhou, Xiao-jia Wang, Hong-chuan Jin, Zhan-hong Chen
Summary: This study retrospectively collected clinical data of patients with HER2-positive eBC and found that the sequential use of PLD and trastuzumab showed a lower incidence of clinical cardiotoxicity compared to conventional treatment, presenting as asymptomatic decreased LVEF.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Toxicology
Chanisa Thonusin, Wichwara Nawara, Thawatchai Khuanjing, Nanthip Prathumsup, Apiwan Arinno, Benjamin Ongnok, Busarin Arunsak, Sirawit Sriwichaiin, Siriporn C. Chattipakorn, Nipon Chattipakorn
Summary: This study investigated the changes in blood and cardiac metabolome levels following treatment with doxorubicin and trastuzumab, and their association with cardiac dysfunction and injury. The study found that there were distinct patterns of metabolome alterations between the two treatment groups, and that the constituents of the blood metabolome may serve as non-invasive biomarkers for assessing the severity and prognosis of heart failure induced by these drugs.
ARCHIVES OF TOXICOLOGY
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)